Home › Compare › HUZNF vs ABBV
HUZNF yields 2666.67% · ABBV yields 3.06%● Live data
📍 HUZNF pulled ahead of the other in Year 1
Combined, HUZNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of HUZNF + ABBV for your $10,000?
Huazhang Technology Holding Limited, an investment holding company, engages in the research, development, manufacture, and sale of industrial automation systems and sludge treatment products in the People's Republic of China. It operates through four segments: Industrial Products, Project Contracting Services, Environmental Products, and Supporting Services. The company offers paper-making machines and equipment; design, procurement, and installation services; and wastewater treatment and waste recycling services. It also provides after-sales services; computer software and hardware, and technical services; and logistics and warehousing services, as well as trades in electronic parts. In addition, Huazhang Technology Holding Limited engages in the design, manufacture, and sale of pulping and papermaking equipment and provision of the after-sales services. The company was founded in 1993 and is headquartered in Hangzhou, China. Huazhang Technology Holding Limited is a subsidiary of Florescent Holdings Limited.
Full HUZNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.